Forest Laboratories Inc., of New York, reported that a pivotal phase III trial testing a combination of nebivolol and Basel, Switzerland-based Novartis AG's Diovan (valsartan) met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at eight weeks in patients with hypertension.